Charles River Laboratories International, Inc. (CRL) closed at $337.24 on November 7, 2026, posting a single-session gain of 7.80% that pushed the contract research organization's market capitalization to $15 billion.
Despite the strong daily move, the stock remains under pressure on a weekly basis, having shed 6.25% over the past seven days. The divergence between the daily and weekly figures suggests the session's advance follows a period of notable selling pressure.
Zooming out further, the 30-day picture is more constructive. CRL has gained 12.33% over the past month, indicating that Thursday's rally contributes to a broader recovery trend from earlier in that window.
Charles River Laboratories provides drug discovery and development services to the pharmaceutical and biotechnology industries. The stock's recent volatility reflects the cross-currents of short-term pressure and longer-term momentum that have characterized its price action heading into mid-November 2026.
